蛋白质组学在唐氏综合征产前筛查中的应用  

Application of Proteomics in Prenatal Screening for Down′s Syndrome

作　　者：赵晟隆[1] 张为远[1] ZHAO Shenglong;ZHANG Weiyuan(Department of Perinatal Medicine,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100026,China)

机构地区：[1]首都医科大学附属北京妇产医院围产医学部,北京100026

出　　处：《医学综述》2021年第11期2228-2232,共5页Medical Recapitulate

摘　　要：唐氏综合征筛查是减少和避免唐氏综合征新生儿出生的有效途径,但母体血清学检查的特异性低、假阳性率高,需要寻找新的生物标志物来提高唐氏综合征筛查的效率。蛋白质组学技术的发展为研究组织或体液中蛋白质的分布提供了新的机会,在疾病或病理状态下优先呈现和鉴定的蛋白质或多肽非常适合作为疾病特异性诊断的标志物。近年来,越来越多的研究致力于利用蛋白质组学技术寻找唐氏综合征的候选标志物,可能有助于提高唐氏综合征产前筛查的敏感性和特异性。未来还需要更多的临床研究来验证大样本队列研究中发现的差异蛋白,并确定其是否独立于目前母体血清生物标志物。Maternal blood Down′s syndrome screening is an effective way to reduce and avoid the birth of newborns with Down′s syndrome.However,due to its low specificity and high false positive rate,it is necessary to find new biomarkers to improve the efficiency of Down′s syndrome screening.The development of proteomics technology provides a new platform to study the distribution of proteins in tissues or body fluids.Proteins or peptides that are preferentially presented and identified under diseases or pathological conditions are very suitable to be used as specific diagnostic markers.In recent years,more and more studies are devoted to the use of proteomics technology to find candidate markers of fetal Down′s syndrome,which may improve the sensitivity and specificity of Down′s syndrome prenatal screening.In the future,more clinical studies are needed to verify the differential proteins found in large-sample cohort studies and determine whether they are independent from the current maternal serum biomarkers.

关 键 词：唐氏综合征 蛋白质组学 产前筛查 

分 类 号：R714.245[医药卫生—妇产科学]